The Growing Role of AI in Cancer Treatment

Published Date: 16 Jun 2026

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Read Full News

Latest News

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Latest News

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

News All Time

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Screening tests that are non-invasive show promise in detecting colorectal cancer.

O. A. J. Simpson passes away from cancer.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

4.

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement

5.

Kate Middleton Reaches Cancer Treatment Milestone

1.

MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps

2.

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care

3.

Decoding Hamartomas: Understanding Their Causes and Symptoms

4.

Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health

5.

Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

3.

Navigating the Complexities of Ph Negative ALL - Part XV

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

5.

Thromboprophylaxis In Medical Settings

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

The Growing Role of AI in Cancer Treatment

Latest News

Combined Models With AI Improve Breast Cancer Prediction

Induction Immunotherapy Has Durable Survival Benefit in LACC

Time to Rethink Maintenance Pemetrexed in NSCLC?

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

Todays Updates

Asian Women With Breast Cancer Outlive White Peers

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

Latest News

News All Time

PSA Screening May Modestly Curb Prostate Cancer Deaths

Capivasertib Wins Metastatic Prostate Cancer Approval

Belzutifan Plus Pembro Approved for Adjuvant RCC

Simpler Screening Criteria Could Catch More Lung Cancers

Breast Cancer Genetic Testing Need in Black Women Identified

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Smartphone App Detects Eye Cancers From Photos

Novel ADC Improves Survival in Metastatic TNBC

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Proton Therapy Fails to Beat IMRT in Prostate Cancer

Chiauranib Slows Platinum-Resistant Ovarian Cancer

Snus Linked to Gingival Damage, Raising Safety Questions

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Therapy Combo Improves Radiographic PFS in Prostate Cancer

Teclistamab Alone Ups Previously Treated Myeloma Survival

Recommended News For You

Research indicates that combining AI models enhances the ability to predict breast cancer risk.

Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic